Amphastar Pharmaceuticals (NASDAQ:AMPH) Coverage Initiated by Analysts at Barclays

Barclays began coverage on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a report released on Tuesday morning, MarketBeat Ratings reports. The firm issued an equal weight rating and a $30.00 target price on the stock.

Other analysts have also recently issued research reports about the company. Needham & Company LLC decreased their target price on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Bank of America boosted their price target on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a report on Tuesday, August 26th. Weiss Ratings restated a “hold (c)” rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 1st. Finally, Zacks Research cut shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 14th. Two equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $31.00.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH opened at $25.65 on Tuesday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.21 and a current ratio of 3.12. Amphastar Pharmaceuticals has a twelve month low of $20.39 and a twelve month high of $45.39. The firm’s 50 day moving average price is $25.59 and its 200 day moving average price is $25.65. The firm has a market cap of $1.18 billion, a PE ratio of 11.35, a PEG ratio of 7.29 and a beta of 0.91.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.10. Amphastar Pharmaceuticals had a net margin of 15.43% and a return on equity of 19.70%. The business had revenue of $191.84 million during the quarter, compared to analysts’ expectations of $186.90 million. As a group, research analysts expect that Amphastar Pharmaceuticals will post 3.49 EPS for the current fiscal year.

Insider Activity at Amphastar Pharmaceuticals

In other news, Director Floyd F. Petersen sold 16,679 shares of the business’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $26.49, for a total transaction of $441,826.71. Following the completion of the transaction, the director owned 75,531 shares of the company’s stock, valued at approximately $2,000,816.19. The trade was a 18.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 4,179 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total transaction of $113,250.90. Following the completion of the transaction, the director directly owned 35,183 shares of the company’s stock, valued at approximately $953,459.30. The trade was a 10.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 21,858 shares of company stock valued at $581,313. Company insiders own 27.10% of the company’s stock.

Institutional Trading of Amphastar Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMPH. Dimensional Fund Advisors LP boosted its position in shares of Amphastar Pharmaceuticals by 7.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,755,665 shares of the company’s stock valued at $46,789,000 after purchasing an additional 128,781 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its position in shares of Amphastar Pharmaceuticals by 11.5% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company’s stock worth $36,632,000 after buying an additional 130,672 shares during the period. Epoch Investment Partners Inc. increased its stake in shares of Amphastar Pharmaceuticals by 14.5% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company’s stock valued at $36,565,000 after acquiring an additional 160,034 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Amphastar Pharmaceuticals by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 973,237 shares of the company’s stock valued at $22,348,000 after acquiring an additional 18,161 shares during the period. Finally, Marshall Wace LLP boosted its stake in Amphastar Pharmaceuticals by 3.0% during the third quarter. Marshall Wace LLP now owns 874,068 shares of the company’s stock worth $23,294,000 after acquiring an additional 25,383 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.